On April 11, 2014, Yamamoto Corporation held a press conference at MyDome Osaka announcing the sale of its medical equipment product in the U.S.
Yamamoto Corporation has received permission to sell medical equipment from the U.S. Food and Drug Administration (FDA), and our infrared ray emitting Biorubber has been registered as a medical equipment product. This product’s medical equipment permission number and category can be found on the FDA’s website (FDA link).
In the U.S. market, we plan to launch sales promotion activities centering on Yamamoto Biotechnology K.K. (California, U.S.) from May.
In Japan, the infrared ray spectral emittance of infrared ray emitting medical equipment must be 60% or higher. However, in the U.S., standards are more rigid, where the value is 80% or higher. Yamamoto Corporation’s Biorubber material has been proven by several public institutions in Japan to have a spectral emittance of 83% to 86%.
Furthermore, our company’s Biorubber is truly an eco-material, as it emits infrared rays without the need for heat or using any power source. This is opposed to conventional infrared ray emitting equipment, available domestically and overseas, which heats up and emits rays using power (100V power supply, batteries).
Yamamoto Corporation is also taking this opportunity to launch Biorubber leasing services for businesses using the “healthy company” management concept and those aspiring to become “healthy companies,” both of which are currently making headlines in Japan.
Pricing has been an issue when using Biorubber for healthy management; however, we will support companies based on the healthy company concept through lease agreements.
Aging society will inevitably increase due to the “retirement age extension” and “reemployment of the elderly.” Companies must unify and help promote the health of their workers.
Yamamoto Corporation is aiming for the Biorubber medical equipment product to be used widely, from small- to medium-sized companies to major companies.